Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28–29 September 2018

Abstract

The 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Saskatoon, Saskatchewan, 28–29 September 2018. This interactive multidisciplinary conference is attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancers. In addition, invited speakers from other provinces participate. Surgical, medical, and radiation oncologists, and allied health care professionals participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancers.

Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada

“…Post hoc retrospective analysis of pivotal trials and several meta-analyses have demonstrated overall survival (OS) improvements with the addition of EGFR inhibitors to chemotherapy versus chemotherapy +/− bevacizumab in patients with 1L RAS wild-type (WT) left-sided mCRC [ 12 , 13 , 14 , 15 , 16 ]. As such, clinical and molecular markers including PTL should be taken into consideration to guide treatment decisions related to 1L mCRC, as recommended by clinical practice guidelines [ 17 , 18 ] and several Canadian consensus papers [ 19 , 20 , 21 , 22 , 23 ]. The randomized controlled phase 3 PARADIGM study prospectively demonstrated that panitumumab added to mFOLFOX6 led to a median OS benefit of 3.6 months in the left-sided population over bevacizumab plus mFOLFOX6 [ 24 ].…”